1 / 39

Chapter 20

Chapter 20. ACE Inhibitors and Angiotensin Receptor Blockers. Drug Overview. Angiotensin-Converting Enzyme Inhibitors Sulfhydryl-containing: captopril Dicarboxylic-containing: linsinopril HCl, benazepril HCl, enalapril maleate, moexipril HCl; perindopril; ramipril; trandolapril

francisl
Download Presentation

Chapter 20

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 20 ACE Inhibitors and Angiotensin Receptor Blockers

  2. Drug Overview • Angiotensin-Converting Enzyme Inhibitors • Sulfhydryl-containing: captopril • Dicarboxylic-containing: linsinopril HCl, benazepril HCl, enalapril maleate, moexipril HCl; perindopril; ramipril; trandolapril • Phosphorus-containing: fosinopril sodium

  3. Drug Overview • Angiotensin II Receptor Blockers • losartan, candesartan, eprosartan, irbesartan, olmesartan, telmisartan, valsartan

  4. Indications • Labeled Uses: ACEIs • HTN, CHF, MI, left ventricular dysfunction, diabetic neuropathy • Unlabeled Uses: ACEIs • Captopril: Hypertensive crisis • In General, ACEIs and ARBs Are Equally Effective • Both Classes Lack Serious Adverse Reactions

  5. Indications • Most Common and Treatment-Limiting Side Effect of ACEIs Is Cough: 20% of All Users • Most Serious AE of ACEIs Is Angioedema • Other Serious SEs of ACEIs and ARBs Include Hyperkalemia, Hypotension, and Acute Renal Failure • Abrupt Withdrawal Has Not Resulted in Rebound Hypertension

  6. Mechanism of Action • ACEIs Block Angiotensin-Converting Enzyme (ACE) • ACE: Responsible for the conversion of angiotensin I to angiotensin II • Angiotensin II: Potent vasoconstrictor and stimulus for aldosterone release from adrenal glands • Reduction in aldosterone results in less water absorption and sodium/potassium exchange in the distal renal tubule • Causing a slight increase in serum potassium

  7. Mechanism of Action • ACEIs Inhibit Breakdown of Bradykinin (Vasodilator) by Blocking the Enzyme Kinase II • Thought to be the cause of cough SE • ARBs Block Effects of Angiotensin II by Blocking the Binding of Angiotensin II to Its Receptors • Do not affect bradykinin • Receptor affinity is highest by candesartan > irbesartan > eprosartan > telmisartan > valsartan > losartan

  8. Mechanism of Action • ARBs Differ from ACEIs in Some Respects • ARBs are more active against AT1 receptors than are ACEIs • ACE inhibition is not associated with increased levels of angiotensin II • ACEIs may increase angiotensin levels to a greater extent than ARBs • ACEIs increase levels of bradykinin

  9. Mechanism of Action • ACE Inhibition Results in Reduction of Systemic Vascular Resistance • No effect or a moderate increase is seen in CO • BP is lowered, and this is not accompanied by changes in HR • Renal perfusion is increased • Renal vascular resistance is decreased • GFR is unchanged

  10. Mechanism of Action • ACE Inhibition in Patients with CHF • Significant decrease in preload through reduction in sodium and water retention • Significant decrease in afterload via decrease in systemic vascular resistance (effects on angiotensin II) • Modest increase in ejection fraction • Decrease in ventricular end-diastolic pressure and volume • Improvement in myocardial energy metabolism

  11. Mechanism of Action • ACE Inhibition in Patients with Renal Impairment • Reduction in arteriolar resistance • Improvement in renal hemodynamics • May improve course for patients with diabetic nephropathy and other renal diseases with glomerular hypertension

  12. Treatment Principles • ACEIs and ARBs Have a Low Incidence of Adverse Reactions • All ACEIs Have Similar Therapeutic Action and Adverse Reactions • Some are prodrugs • Duration of action may differ • Tissue distribution may differ • Most are excreted renally

  13. Treatment Principles • Generally considered safe in patients with mild to moderate renal impairment • Dosage reduction • Fosinopril, lisinopril, and ramipril are eliminated both renally and hepatically • Dehydration and renal insufficiency increase risk of elevated K+ when ACEIs are initiated

  14. Treatment Principles • Advantages of ARBs Over ACEIs • No dry cough • Decreased incidence of angioedema • Second-line treatment because of cost

  15. Treatment Principles • Hypertension • Useful in treatment of HTN with concomitant illnesses • DM, renal insufficiency, left ventricular dysfunction, CHF • 50% to 60% of whites respond well • African American patients do not respond as well • Addition of low-dose thiazide diuretic provides efficacy comparable with that of whites • BP reduction may be progressive with maximal results in 2 to 4 weeks

  16. Treatment Principles • Hypertension (cont’d) • BP reduction may be progressive with maximal results in 2 to 4 weeks • Regression of left ventricular hypertrophy • ALLHAT trial • ACEI was less cardioprotective than thiazide diuretics • No effect on glucose, cholesterol, or uric acid levels

  17. Treatment Principles • Hypertension (cont’d) • Studies show an increase in insulin sensitivity and a modest reduction in plasma glucose • Minimize or prevent diuretic-induced elevations in cholesterol and uric acid levels • Seven trials found that risk of developing DM was 22% less than that of other agents or placebo

  18. Treatment Principles • Hypertension (cont’d) • Three trials (DREAM, NAVIGATOR, and ONTARGET) are under way • To determine whether ACEIs and ARBs or combination therapy is more effective in preventing DM • Antihypertensive effects of ARBs are comparable with those of ACEIs

  19. Treatment Principles • Post–Myocardial Infarction/High Risk of Cardiovascular Events • ACEIs • Prevent ventricular remodeling and improve endothelial function after MI • Decrease action of fibrin • 2004 ACC/AHA Guidelines recommend that ACEIs should be initiated within 24 hours for patients who are stable with STEMI

  20. Treatment Principles • Post–Myocardial Infarction/High Risk of Cardiovascular Events • ACEIs (cont’d) • Should be avoided in patients with • ACEI allergy • Renal failure • Hypotension (sys BP 90 to 100 mm Hg or 30 mm Hg below baseline) • Shock • H/O bilateral renal artery stenosis • Prior worsening of renal function with ACEIs

  21. Treatment Principles • Post–Myocardial Infarction/High Risk of Cardiovascular Events • ACEIs (cont’d) • Clinically proven to improve survival in patients with serum creatinine concentrations above 3 mg/dl • Study: 20,000 patients 65 years of age who had an MI and impaired LVF and those on ASA

  22. Treatment Principles • Post–Myocardial Infarction/High Risk of Cardiovascular Events • ACEIs (cont’d) • HOPE trial: Landmark study of patients at high risk of cardiovascular events • Trial halted after 4.5 years because ramipril was shown to reduce the following events: • Primary endpoint • Cardiovascular mortality • Nonfatal MI • Stroke • New cases of DM

  23. Treatment Principles • Post–Myocardial Infarction/High Risk of Cardiovascular Events • ACEIs (cont’d) • HOPE trial • Benefit was seen within the first year • Benefit independent of age and gender • Benefits were apparent in patients with significant comorbidities • Benefits were comparable with those seen in trials of statin drugs • Trials done on ACEIs, but it is felt that ARBs would deliver comparable results

  24. Treatment Principles • Chronic Heart Failure • ACEIs should be given to all patients with asymptomatic or symptomatic heart failure • Reduction in ventricular dilation • Restoration of heart muscle to normal elliptical shape • Reverse ventricular remodeling • Reduce preload, afterload, HR, systemic BP, and renovascular resistance • Increase renal blood flow

  25. Treatment Principles • Chronic Heart Failure (cont’d) • Patient should be well hydrated prior to initiation of ACEI to avoid renal failure • Meta-analysis of more than 12,000 patients • Reduced total mortality • Lower hospital readmissions • Reduction in incidence of MI • ARB use in HF may be as effective as or slightly less effective than ACEIs • 2005 ACC/AHA task force recommends ARBs inpatients who cannot tolerate ACEIs

  26. Treatment Principles • Chronic Heart Failure (cont’d) • Benefits of ACEIs in the African American population have not been strong • V-HeFT and SOLVD found higher rates of progressive HF and overall mortality in this population

  27. Treatment Principles • Prevention of Renal Failure in DM • ACEIs and ARBs have been shown to slow progression of diabetic nephropathy • Most trials have been done with the use of ACEIs; ARBs are felt to have similar efficacy • These medications are indicated for all diabetic patients with microalbuminuria or macroalbuminuria • American Diabetes Association 2004 Statement on the Use of ACEIs and ARBs

  28. How to Monitor • Baseline and Periodic • Electrolyte panel • Serum blood urea nitrogen and creatinine • UA • WBC • Once stable: Recheck serum creatinine and potassium at 2 and 4 weeks • No risk factors for renal deterioration: Recheck every 3 to 6 months

  29. How to Monitor • Baseline and Periodic (cont’d) • Supine BP weekly while titrating • Angioedema without urticaria • 50% of cases develop within 1 week of initiation

  30. Patient Variables • Geriatrics • Lower dose may be needed in patients with renal or hepatic insufficiency • Useful in elderly • Pediatrics • Safety and efficacy have not been established • Irbesartan is indicated in children older than 6 years

  31. Patient Variables • Pregnancy • ACEIs and ARBs are associated with significant fetal risk • CV and CNS abnormalities documented in more than three and five times as many infants exposed to ACEIs in the first trimester • Race • Less effective in blacks when used as monotherapy • Use in combination with diuretics has been successful in this population

  32. Patient Education • Do Not Take Two Doses at the Same Time • Common SEs Include: • Nonproductive cough • Dizziness or light-headedness • Red Flags • Swelling, SOB, difficulty swallowing, hives, urticaria, fainting, cloudy urine, sore throat, fever and sudden onset of abdominal pain, diarrhea and vomiting • Irregular HR, leg weakness, numbness/tingling in hands or feet, extreme nervousness • Avoid Use of Potassium-Containing Medicines or Salt Substitutes While on This Medication

  33. Lisinopril • Contraindications • Warnings • First-dose effect • Precautions

  34. Lisinopril: Pharmacokinetics • See Table 20-2

  35. Lisinopril: Adverse Effects • See Table 20-3

  36. Lisinopril: Drug Interactions • See Table 20-4

  37. Lisinopril: Dosage and Administration • 2 Weeks for BP Reduction to Be Seen, and 4 Weeks for Full Effect • Food Affects Rate But Not Extent of Absorption of Fosinopril • Captopril and Moexipril Are Taken 1 Hour Before Meals • Ramipril Caps Can Be Opened and Mixed with Food • Rate and Absorption of Quinapril Reduced by 25% When Taken with High-Fat Meal

  38. Lisinopril: Dosage and Administration • Decrease Dose in Patients with Renal Insufficiency: lisinopril, captopril, enalapril, ramipril

  39. Lisinopril: Dosage and Administration • See Table 20-5

More Related